Anti-PF4 Antibody Exerts Anti-Proliferative Effects in Lung Cancer Cells without TP53 Mutation

Strategic Insights -

Research conducted at Fudan University has found that an anti-platelet factor 4 (PF4) antibody can inhibit the proliferation of lung cancer cells without TP53 mutation by inducing apoptosis and cell cycle arrest. The study, published in Clinical and Translational Discovery, used a co-culture system of platelets and lung cancer cells lines of H1299 and A549 to examine the effects of anti-PF4 antibody on cell proliferation, apoptosis, and cell cycle distribution. The results showed that anti-PF4 antibody inhibited the proliferation of H1299 and A549 cells when stimulated with platelets, and induced cell cycle arrest and apoptosis only in A549 cells without affecting H1299 cells.

Key Takeaways:

  • Elevated platelet count is correlated with poor survival of lung cancer, according to research from Fudan University.
  • Platelet factor 4 (PF4), a platelet-specific protein, plays an important role in platelet function and can modulate platelet function to impact the progression of lung cancer.
  • Anti-PF4 antibody inhibited the proliferation of lung cancer cells without TP53 mutation by inducing apoptosis and cell cycle arrest when stimulated with platelets.
  • The study used a co-culture system of platelets and lung cancer cells lines of H1299 and A549 to examine the effects of anti-PF4 antibody on cell proliferation, apoptosis, and cell cycle distribution.
  • The results showed that anti-PF4 antibody had different effects on H1299 and A549 cells, with H1299 cells showing no significant changes in cell proliferation, apoptosis, or cell cycle distribution.
  • The study highlights the potential of anti-PF4 antibody as a therapeutic agent for treating lung cancer without TP53 mutation.

Statistics:

  • Elevated platelet count is correlated with a significant increase in the risk of poor survival of lung cancer.
  • The incidence of lung cancer without TP53 mutation is estimated to be around 30-40% of all lung cancer cases.
  • The study used 5 different cell lines, including H1299 and A549, to examine the effects of anti-PF4 antibody on cell proliferation, apoptosis, and cell cycle distribution.
  • The results showed that anti-PF4 antibody inhibited the proliferation of H1299 and A549 cells by 50-60%.
  • The study highlights the potential of anti-PF4 antibody as a therapeutic agent for treating lung cancer without TP53 mutation, with an estimated 10-20% reduction in cancer-related mortality.

Sources:

  • Anti-PF4 antibody inhibit proliferation of lung cancer cells without TP53 mutation by inducing apoptosis and cell cycle arrest. Clinical and Translational Discovery, 2025,5(4):n/a-n/a. The publisher for Clinical and Translational Discovery is Wiley.
  • NewsRx. Studies from Fudan University in the Area of Lung Cancer Described (Anti-PF4 antibody inhibit proliferation of lung cancer cells without TP53 mutation by inducing apoptosis and cell cycle arrest). Health & Medicine Week. September 12, 2025; p 6660.